RecruitingPhase 2NCT05305859

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML)

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

30 participants

Start Date

Jan 12, 2022

Study Type

INTERVENTIONAL

Conditions

Leukemia, Myeloid, Acute Refractory Leukemia Relapsed Adult AML

Summary

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial tests a three-drug combination — venetoclax, chidamide, and azacitidine (VCA) — for people with relapsed or refractory acute myeloid leukemia (AML), meaning their blood cancer came back or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older with a confirmed AML diagnosis that has relapsed or is no longer responding to treatment - You have adequate kidney, liver, and heart function - You have a life expectancy of at least 3 months and good enough physical function (ECOG 0–2) **You may NOT be eligible if...** - You have a subtype called acute promyelocytic leukemia (APL) - Your leukemia has spread to the brain or spinal fluid - You have serious uncontrolled heart disease (very slow heart rate or unstable conditions) - You have had recent prior cancer treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.